Shanghai Medicilon Inc (SHG:688202) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Medicilon Inc (688202)
Shanghai Medicilon Inc (SHG:688202) has a market capitalization of $1.12 Billion (CN¥7.66 Billion) as of June 23, 2026. Listed on the SHG stock exchange, this China-based company holds position #8570 globally and #2124 in its home market, demonstrating a 9.47% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Medicilon Inc's stock price CN¥56.99 by its total outstanding shares 134352184 (134.35 Million). Review Shanghai Medicilon Inc balance sheet liabilities to assess the company's total debt and financial obligations.
Shanghai Medicilon Inc Market Cap History: 2019 to 2026
Shanghai Medicilon Inc's market capitalization history from 2019 to 2026. Data shows growth from $579.14 Million to $1.12 Billion (7.25% CAGR).
Shanghai Medicilon Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Medicilon Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.95x
Shanghai Medicilon Inc's market cap is 0.95 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $579.14 Million | $449.39 Million | $66.57 Million | 1.29x | 8.70x |
| 2020 | $1.56 Billion | $665.96 Million | $129.39 Million | 2.34x | 12.06x |
| 2021 | $4.83 Billion | $1.17 Billion | $282.22 Million | 4.14x | 17.10x |
| 2022 | $2.99 Billion | $1.66 Billion | $338.24 Million | 1.80x | 8.84x |
| 2023 | $1.34 Billion | $1.37 Billion | -$33.21 Million | 0.98x | N/A |
| 2024 | $593.14 Million | $1.04 Billion | -$330.85 Million | 0.57x | N/A |
| 2025 | $1.11 Billion | $1.16 Billion | -$167.83 Million | 0.95x | N/A |
Competitor Companies of 688202 by Market Capitalization
Companies near Shanghai Medicilon Inc in the global market cap rankings as of June 23, 2026.
Key companies related to Shanghai Medicilon Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Shanghai Medicilon Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Shanghai Medicilon Inc's market cap moved from $579.14 Million to $ 1.12 Billion, with a yearly change of 7.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.12 Billion | +1.05% |
| 2025 | CN¥1.11 Billion | +86.94% |
| 2024 | CN¥593.14 Million | -55.88% |
| 2023 | CN¥1.34 Billion | -55.06% |
| 2022 | CN¥2.99 Billion | -38.02% |
| 2021 | CN¥4.83 Billion | +209.30% |
| 2020 | CN¥1.56 Billion | +169.46% |
| 2019 | CN¥579.14 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Shanghai Medicilon Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.12 Billion USD |
| MoneyControl | $1.12 Billion USD |
| MarketWatch | $1.12 Billion USD |
| marketcap.company | $1.12 Billion USD |
| Reuters | $1.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in … Read more